VTGN
Income statement / Annual
Last year (2024), VistaGen Therapeutics, Inc.'s total revenue was $1.06 M,
a decrease of 568.72% from the previous year.
In 2024, VistaGen Therapeutics, Inc.'s net income was -$29.36 M.
See VistaGen Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
03/31/2024 |
03/31/2023 |
03/31/2022 |
03/31/2021 |
03/31/2020 |
03/31/2019 |
03/31/2018 |
03/31/2017 |
03/31/2016 |
03/31/2015 |
| Operating Revenue |
$1.06 M |
-$227,000.00 |
$1.11 M |
$1.09 M |
$0.00 |
$0.00 |
$0.00 |
$1.25 M |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$103,100.00
|
$91,200.00
|
$80,700.00
|
$0.00
|
$53,500.00
|
$0.00
|
| Gross Profit |
$1.06 M
|
-$227,000.00
|
$1.11 M
|
$1.09 M
|
$0.00
|
$0.00
|
$0.00
|
$1.25 M
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
| Research and Development Expenses |
$20.02 M
|
$44.38 M
|
$35.41 M
|
$11.93 M
|
$13.37 M
|
$17.10 M
|
$7.76 M
|
$5.20 M
|
$3.93 M
|
$2.43 M
|
| General & Administrative Expenses |
$14.06 M
|
$14.66 M
|
$10.45 M
|
$7.10 M
|
$6.60 M
|
$7.43 M
|
$6.44 M
|
$5.87 M
|
$13.92 M
|
$4.25 M
|
| Selling & Marketing Expenses |
$0.00
|
$1.90 M
|
$2.80 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$14.06 M
|
$14.66 M
|
$13.25 M
|
$7.10 M
|
$6.60 M
|
$7.43 M
|
$6.44 M
|
$5.87 M
|
$13.92 M
|
$4.25 M
|
| Other Expenses |
$0.00
|
$0.00
|
$232,000.00
|
-$400.00
|
-$827,000.00
|
-$48,700.00
|
-$428,000.00
|
$426,800.00
|
-$2,300.00
|
-$233,000.00
|
| Operating Expenses |
$34.09 M
|
$59.04 M
|
$48.89 M
|
$19.02 M
|
$19.97 M
|
$24.53 M
|
$14.20 M
|
$11.50 M
|
$17.85 M
|
$6.68 M
|
| Cost And Expenses |
$34.09 M
|
$59.04 M
|
$48.89 M
|
$19.02 M
|
$19.97 M
|
$24.53 M
|
$14.20 M
|
$11.50 M
|
$17.85 M
|
$6.68 M
|
| Interest Income |
$0.00
|
$49,000.00
|
$20,000.00
|
$15,000.00
|
$45,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$5,000.00
|
| Interest Expense |
$0.00
|
$23,000.00
|
$0.00
|
$13,000.00
|
$15,000.00
|
$8,000.00
|
$8,900.00
|
$5,000.00
|
$777,000.00
|
$4.62 M
|
| Depreciation & Amortization |
$568,000.00
|
$532,000.00
|
$711,100.00
|
$477,600.00
|
$103,100.00
|
$91,200.00
|
$80,700.00
|
$54,900.00
|
$53,500.00
|
$59,100.00
|
| EBITDA |
-$32.45 M |
-$58.74 M |
-$47.05 M |
-$17.44 M |
-$20.65 M |
-$24.47 M |
-$14.25 M |
-$9.77 M |
-$17.80 M |
-$6.72 M |
| EBITDA Ratio |
-30.5
|
258.16
|
-42.22
|
-16.34
|
0
|
0
|
0
|
-8.15
|
0
|
0
|
| Operating Income Ratio |
-31.03
|
260.41
|
-43.09
|
-16.46
|
0
|
0
|
0
|
-8.2
|
0
|
0
|
| Total Other Income/Expenses Net |
$3.66 M
|
$26,000.00
|
$19,900.00
|
$2,200.00
|
$30,100.00
|
-$30,700.00
|
-$143,900.00
|
-$4,600.00
|
-$29.37 M
|
-$7.11 M
|
| Income Before Tax |
-$29.36 M
|
-$59.24 M
|
-$47.76 M
|
-$17.93 M
|
-$20.77 M
|
-$24.59 M
|
-$14.34 M
|
-$10.25 M
|
-$47.22 M
|
-$13.88 M
|
| Income Before Tax Ratio |
-27.59
|
260.63
|
-43.07
|
-16.46
|
0
|
0
|
0
|
-8.2
|
0
|
0
|
| Income Tax Expense |
$4,000.00
|
$6,000.00
|
$3,400.00
|
$2,600.00
|
$2,600.00
|
$2,600.00
|
$2,400.00
|
$2,400.00
|
$2,300.00
|
$2,400.00
|
| Net Income |
-$29.36 M
|
-$59.25 M
|
-$47.76 M
|
-$17.93 M
|
-$20.77 M
|
-$24.59 M
|
-$14.35 M
|
-$10.26 M
|
-$47.22 M
|
-$13.89 M
|
| Net Income Ratio |
-27.6
|
260.66
|
-43.07
|
-16.46
|
0
|
0
|
0
|
-8.2
|
0
|
0
|
| EPS |
-1.52 |
-8.51 |
-7.24 |
-6.25 |
-14.21 |
-25.83 |
-30.98 |
-40.85 |
-801.28 |
-318.27 |
| EPS Diluted |
-1.52 |
-8.51 |
-7.24 |
-6.25 |
-14.21 |
-25.83 |
-30.98 |
-40.85 |
-801.27 |
-315.87 |
| Weighted Average Shares Out |
$19.35 M
|
$6.96 M
|
$6.60 M
|
$2.87 M
|
$1.46 M
|
$952,082.00
|
$463,001.00
|
$251,054.00
|
$58,931.00
|
$43,629.00
|
| Weighted Average Shares Out Diluted |
$19.35 M
|
$6.96 M
|
$6.60 M
|
$2.87 M
|
$1.46 M
|
$952,082.00
|
$463,001.00
|
$251,054.00
|
$58,932.00
|
$43,960.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
